Objective  To determine the near-term therapeutic efficacy and toxicity of a nedaplatin/taxane regimen in patients with advanced gynecological neoplasms by comparing this regimen with oxaliplatin/taxane and carboplatin/taxane combination chemotherapy.

  Methods  From January 2009 to June 2011, chemotherapy regimens containing nedaplatin/taxane(Group 1), oxaliplatin/taxane (Group 2), or carboplatin/ taxane(Group 3) was given to 137 patients with advanced gynecological neoplasms.A retrospective comparative study of the curative effect and toxicity of the chemotherapies was conducted in the three treatment groups.

  Results  The effective response rates were 81.82%, 80.43%, and 76.60%in Groups 1, 2, and 3, respectively.However, there was no statistically significant difference among the three groups.Both gastrointestinal toxicity and hepatic toxicity were lower in Group 1 than in Group 2, but the difference was not statistically significant(P > 0.05).The incidence of neutropenia was significantly lower in Group 1 than in Group 2(P = 0.01).The incidence of thrombopenia was higher in Group 1 than in Group 3(42.03%and 37.42%, respectively), but the difference was not statistically significant(P > 0.05).Symptoms of anaphylaxis and nephrotoxicity were not observed in Group 1, although mild neurotoxicity was observed in a few patients.

  Conclusion  There was no statistically significant difference between the curative effects of the combined chemotherapy regimen of the new-generation anticancer drugs oxaliplatin and carboplatin.The main toxicity of nedaplatin was myelosuppression and gastrointestinal toxicity.There was no significant difference among the toxicities of the combined chemotherapy of nedaplatin, oxaliplatin, and carboplatin.Thus, any of these drugs can be used to treat advanced gynecological neoplasms based on the specific clinical conditions of patients.